CIK 0001832038
- Emerging growth company
Invivyd, Inc.
Sign in to watch- Ticker
- IVVD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 851403134
- Phone
- +1 781-819-0080
- Business address
- 205 CHURCH STREET, NEW HAVEN, CT
- Former names
- Adagio Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $86,839
- in 5 filings, $87K under 10b5-1 plans
Net −$86,839. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Andersen Jill −$26K Chief Legal Officer, Secretary sold 10% of stake
- Duke William E. −$16K Chief Financial Officer sold 10% of stake
- Green Julie −$16K Chief Human Resources Officer sold 10% of stake
- Lee Timothy Edward −$16K Chief Commercial Officer sold 9% of stake
- Allen Robert D. III −$14K Chief Scientific Officer sold 9% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-10 | MCGUIRE TERRANCE Director | Conversion · Series B Preferred Stock | −583 | 0 | ||
| 2021-08-10 | MCGUIRE TERRANCE Director | Conversion · Series B Preferred Stock | −850 | 0 | ||
| 2021-08-10 | MCGUIRE TERRANCE Director | Conversion · Series B Preferred Stock | −44,076 | 0 | ||
| 2021-08-10 | MCGUIRE TERRANCE Director | Conversion · Series C Preferred Stock | −123,574 | 0 | ||
| 2021-08-10 | MCGUIRE TERRANCE Director | Conversion · Series C Preferred Stock | −2,409 | 0 | ||
| 2021-08-10 | MCGUIRE TERRANCE Director | Conversion · Series C Preferred Stock | −846 | 0 | ||
| 2021-08-10 | MCGUIRE TERRANCE Director | Conversion · Series C Preferred Stock | −1,235 | 0 | ||
| 2021-08-10 | MCGUIRE TERRANCE Director | Conversion · Series C Preferred Stock | −32,016 | 0 | ||
| 2021-08-10 | MCGUIRE TERRANCE Director | Conversion · Series C Preferred | −64,032 | 0 | ||
| 2021-08-10 | Gerngross Tillman U. Chief Executive Officer | Conversion | +25,860,700 | 27,845,995 | ||
| 2021-08-10 | Gerngross Tillman U. Chief Executive Officer | Conversion · Series A Preferred Stock | −5,000,000 | 0 | ||
| 2021-08-10 | Gerngross Tillman U. Chief Executive Officer | Conversion · Series B Preferred Stock | −44,076 | 0 | ||
| 2021-08-10 | Gerngross Tillman U. Chief Executive Officer | Conversion · Series C Preferred Stock | −128,064 | 0 | ||
| 2021-08-10 | Adimab, LLC 10% owner | Conversion | +25,860,700 | 27,845,995 | ||
| 2021-08-10 | Adimab, LLC 10% owner | Conversion · Series A Preferred Stock | −5,000,000 | 0 | ||
| 2021-08-10 | Adimab, LLC 10% owner | Conversion · Series B Preferred Stock | −44,076 | 0 | ||
| 2021-08-10 | Adimab, LLC 10% owner | Conversion · Series C Preferred Stock | −128,064 | 0 | ||
| 2021-08-10 | Redmile Group, LLC 10% owner | Conversion | +1,920,960 | 1,920,960 | ||
| 2021-08-10 | Redmile Group, LLC 10% owner | Purchase | +1,470,000 | $17.00 | $25.0M | 3,390,960 |
| 2021-08-10 | Redmile Group, LLC 10% owner | Conversion · Series C Preferred Stock | −1,920,960 | 0 |
Page 11 of 12 · 225 trades